Combined Use of Subclinical Hydroxyurea and CHK1 Inhibitor Effectively Controls Melanoma and Lung Cancer Progression, With Reduced Normal Tissue Toxicity Compared to Gemcitabine
Molecular Oncology - Netherlands
doi 10.1002/1878-0261.12497
Full Text
Open PDFAbstract
Available in full text
Date
June 14, 2019
Authors
Publisher
Wiley